FDA rejects J&J premature ejaculation drug

Share this article:
The FDA has rejected Johnson & Johnson's application for its experimental drug to treat premature ejaculation, the company said yesterday.
J&J's Alza unit said it plans to address the questions raised by the FDA in its not approvable letter and continue developing the drug.
Alza did not provide further details on why the FDA did not approve the drug.
In a statement, the J&J unit said it "continues to believe that dapoxetine provides important benefits for men who suffer from (premature ejaculation)."
Currently, there are no FDA approved drugs on the market to treat premature ejaculation, a distinct medical condition recognized by the American Urological Association, among other groups.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.